Healthcare Technology - Personalized Medecine
16 January 2009
View Comments
Santa Clara, CA (OBBeC) - Affymetrix has unveiled that the Coriell Personalized Medicine Collaborative (CPMC), part of the Coriell Institute for Medical Research, has selected its new DMET Plus Product for a national project to identify biologically relevant markers for drug response.
Launched in December 2007, the CPMC has been using the Genome-Wide Human SNP Array 6.0 to identify genes associated with complex health conditions, such as cancer, heart and blood vessel diseases, and diabetes. With the DMET Plus Product, the CPMC will expand these investigations to include direct interrogation of markers for drug metabolism and transport to build a database of genetic information related to drug response.
"Without the DMET Plus Product we would have been confined to an ad hoc, one-off assay which limits us to the narrowest set of biomarkers," said Dr. Michael F. Christman, president and CEO, the Coriell Institute for Medical Research. "In addition, some drug metabolism markers are highly challenging technically and the DMET Plus Product offers us the best chance of measuring them."
According to the announcement, the CPMC plans to enroll 10,000 individuals by the end of 2009, with an ultimate goal of 100,000. The data generated will greatly improve the scientific community's understanding of why some subpopulations and individuals respond to a drug differently than anticipated.
Launched in December 2007, the CPMC has been using the Genome-Wide Human SNP Array 6.0 to identify genes associated with complex health conditions, such as cancer, heart and blood vessel diseases, and diabetes. With the DMET Plus Product, the CPMC will expand these investigations to include direct interrogation of markers for drug metabolism and transport to build a database of genetic information related to drug response.
"Without the DMET Plus Product we would have been confined to an ad hoc, one-off assay which limits us to the narrowest set of biomarkers," said Dr. Michael F. Christman, president and CEO, the Coriell Institute for Medical Research. "In addition, some drug metabolism markers are highly challenging technically and the DMET Plus Product offers us the best chance of measuring them."
According to the announcement, the CPMC plans to enroll 10,000 individuals by the end of 2009, with an ultimate goal of 100,000. The data generated will greatly improve the scientific community's understanding of why some subpopulations and individuals respond to a drug differently than anticipated.
